Skip to Content

Handbook of Clinical Nanomedicine

From Bench to Bedside

Edited by Raj Bawa, Gerald F. Audette, Israel Rubinstein

Pan Stanford – 2014 – 800 pages

Purchasing Options:

  • Pre-Order NowHardback: $495.00
    9789814316170
    February 28th 2015
    Available for pre-order

Description

The enormous advances in nanomedicine in the past decade have necessitated a growing need for an authoritative and comprehensive reference that can be relied upon by scientists, clinicians, students, and policy makers alike. Handbook of Clinical Nanomedicine: From Bench to Bedside is designed to offer a global perspective on the wonders of nanomedicine.

The handbook aims to provide a broad survey of various interconnected topics pertaining to nanomedicine. It is intended to be a stand-alone, easily accessible volume that examines the entire "product wheel" from creation of nanomedical products to final market introduction, all accomplished in a user-friendly format. Specifically, everything from bio-nanomaterials and nanodevices from the R&D stage to patent protection, clinical regulatory aspects, and eventual commercialization is encompassed in this book. In addition to highlighting cutting-edge technologies, the book addresses critical topics such as ethics, safety and toxicity, environmental health, nanoeconomics, business strategy, licensing, intellectual property, FDA law, EPA law, and governmental policy issues. With contributions from international experts, the diverse team of editors has compiled a book that provides a unified perspective to these varied topics. While many books focus on nanomedicine, nanotechnology, or nanoscience, none provides the medical applications of nanotechnology with both a clinical and a business angle. Furthermore, most of the currently available books on the market fail to highlight the truly global nature of nanomedicine.

The handbook provides a comprehensive road map of basic research in nanomedicine as well as clinical applications and commercialization activities. It is essential reading for the novice and expert alike in fields such as medicine, law, biotechnology, pharmaceutical sciences, engineering, biomedicine, policy, future studies, ethics, intellectual property law, licensing, and toxicology. While bridging the gap between basic biomedical research, engineering, and medicine, the handbook provides an understanding of nanotechnology’s use to solve medical problems; current applications and their potential; regulatory environment and policy issues; and intellectual property, licensing, and business activities.

The range of topics covered as well as the international selection of authors is truly impressive. Since the rapidly evolving field of nanomedicine is very diverse and covers physical, chemical, biological, and engineering aspects, the range of the contributing authors accurately reflects this. The book’s multidisciplinary approach and an in-depth focus on nanomedicine, pharmaceutical sciences, materials science, biomedical engineering, and biotechnology will attract a global audience. In short, this book promises to be a standard reference text in this expansive and interdisciplinary field. It is a timely addition to the literature on nanosciences and will undoubtedly serve as a catalyst to stimulate interest in this rapidly growing field.

Contents

General

Science at the nanoscale: Introduction and historical perspective

Song, Haur and Wee

Nanomedicine: Dynamic integration of nanotechnology with biomedical science

Lee, Solanki, Kim, Jung

Defining nanotechnology and nanomedicine – big issue in small science

Bawa

Nano-therapeutics and the future of medicine

Bawa, Bawa and Mehra

Top ten recent nanomedical advances

Swan

Nanosystems, Nanodevices and Imaging Tools

Nanosizing approaches in drug delivery

Chavhan, Petkar and Sawant

Design and development of approved nanopharmaceutical products

Mansour, Park and Bawa

Designing nanocarriers for the effective treatment of cardiovascular diseases

Vaidya and Vyas

Nanoparticles for multi-modality diagnostic imaging and drug delivery

Lockhart and Ho

Magnetic nanoparticles in magnetic resonance imaging: A translational push toward theranostics

Ortega, Yankeelov and Giorgio

Atomic force microscopy for nanomedicine

Sharma and Gimzewski

Advances in the use of nanomedicine for medical imaging

Dearling and Packard

Image-based high-content analysis, stem cells and nanomedicines: A novel strategy for drug discovery

Solomesky, Adalist and Weil

AFM imaging and probing amyloid nanoaggergates

Lyubchenko

Intracellular transport and unpacking of polyplex nanoparticles

Rosenkranz, Khramtsov, Ulasov, Rodichenko and Sobolev

Cell and protein interactions with small-scale diamond materials

Narayan, Boehm and Monteiro-Riviere

Bacterial secretion systems: nanomachines for infection and genetic diversity

Shala, Ferarro and Audette

Viral nanoparticles: Tools for materials science and biomedicine

Steinmetz and Manchester

Clinical Applications

Polysaccharides as nanomaterials for therapeutics

Mizrahy and Peer Diwan

Aptamers in clinical trials

Kanwar, Roy, Kanwar and Bawa

Nanotechnology and the skin barrier: topical and transdermal nanocarrier-based delivery

Labouta and Schneider

Transdermal immunotherapy with synthetic pathogen-like nanomedicines and its clinical application towards the cure of HIV

Lorincz and Lisziewicz

Application of nanotechnology in non-invasive topical gene therapy

Esabahy, Jimena Loureiro and Foldvari

Nanocarriers in the therapy of inflammatory disease

Lamprecht

Nanomedicine challenges in thrombosis

Karagkiozaki

Nanomedicine for cardiovascular disease: Potentials and Challenges

Karagkiozaki

Nanomedicine for acute lung injury/acute respiratory distress syndrome: a shifting paradigm?

Sadikot and Rubinstein

Multilayered nanoparticles for personalized medicine: translation into clinical markets

Prina-Mello

Carbon nanotubes as substrates for neuronal growth

Ménard-Moyon

Polymeric nanoparticles for cancer therapeutics

Verma, Rosen, Meerasa, Yoffe and Gu

Nanotechnology for radiation oncology

Sridhar, Berbeco, Cormack, and Makrigiorgos

Solid lipid nanoparticles and nanostructured lipid carriers for cancer therapy

Uner

Nanoparticles for brain cancer therapy

Agarwal, Tiwari, Agrawal

Complement activation: a capricious immune barrier to nanomedicine clinical application

Szebeni

Regulatory Issues, Toxicology, Intellectual Property and Nano-Ethics

Regulating nanomedicine at the FDA and EPA

Hartman, Bawa, Monica

Regulatory aspects of nanomedicine in Europe

D’Silva

Managing environmental and health risks in the nanotechnology industry

Huan

Toxicity of silicon dioxide nanoparticles in mammalian neural cells

Lai, Jaiswal, Lai, Jandhyam, Leung and Bhushan

An intellectual property primer for nanomedical researchers and engineers

Reese

Strategic intellectual property management – building IP portfolios

Langer

IP Valuation: principles and applications in the nanotechnology industry

Kasznik

Extending patent term for nanomedical inventions – A nexus between the FDA and the patent system

Hopkins

Technology transfer: An overview

Goldstein

Licensing issues in nanotechnology

Brougher

The Tower of Babel: miscommunication within and about nanomedicine

Juliano

Clinical nanobioethical problems: a value approach

Álvarez-Díaz

The audience is the message: nanomedicine as apotheosis or damnatio memoriae

Berube

Author Bio

Raj Bawa, MS., PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm he founded in 2002 and is currently based in Ashburn, VA (USA). He is an inventor, entrepreneur, professor, and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for the past two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery, and biodefense-related scientific, FDA regulatory, and patent law issues. He has served as an advisor, consultant, or expert to numerous global corporations, US government (NIH, NSF), law firms, universities, nonprofits, and NGOs. Since 1999, he has held faculty appointments at Rensselaer Polytechnic Institute (Troy, NY) where he is currently an adjunct professor of biological sciences. Since 2004, he has been an adjunct associate professor of natural and applied sciences at NVCC (Annandale, VA). Since 2012, he has been a scientific advisor to Teva Pharmaceutical Industries, Ltd. (Israel). He previously served as patent legal advisor at Sequoia Pharmaceuticals (Gaithersburg, MD) and as senior scientist at SynerGene Therapeutics, Inc. (Potomac, MD). He recently served as principle investigator for two US National Cancer Institute/SBIR contracts titled "Targeted nanocomplexed iron oxide for early detection with concurrent hyperthermia treatment of cancer" and "A targeted nanocomplex for early detection of lung cancer. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner (6 years) and instructor at the US Patent Academy. He is a life member of Sigma Xi, founding director of the American Society for Nanomedicine, and co-chair of the Nanotech Committee of the American Bar Association. He has authored over 100 publications, co-edited two books, and presented or chaired at over 200 conferences worldwide. He serves on the editorial boards of 16 peer-reviewed journals, including Pharmaceutical Patent Analyst, International Journal of Nanomedicine, Cancer Nanotechnology, Applied Scientific Reports, Recent Patents on Biomedical Engineering, Nanotechnology Law and Business, Recent Patents on Nanotechnology, Journal of Epidemiology and Preventive Medicine, WIRE’s Nanomedicine and Nanobiotechnology, JSM Biotechnology & Biomedical Engineering, Nanomedicine: NBM. Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the US Undersecretary of Commerce, Washington, DC (2001); a Research Fellowship from Rensselaer (1989–1990); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).

Gerald F. Audette, PhD, has been a faculty member at York University in Toronto (Canada) in the Department of Chemistry since 2006. Currently he is an associate professor in the department, and is a member of the Centre for Research on Biomolecular Interactions at York University. He received his doctorate in the Department of Biochemistry at the University of Saskatchewan in Saskatoon, Canada in 2002. Working with Drs. Louis T. J. Delbaere and J. Wilson Quail (1995–2001), Dr. Audette's research focused on the elucidation of the protein-carbohydrate interactions that occur during blood-group recognition, in particular during the recognition of the O blood type, using high-resolution X-ray crystallography. Dr. Audette conducted his postdoctoral research at the University of Alberta (2001–2006) in Edmonton, Canada. Working with Drs. Bart Hazes and Laura Frost, his research again utilized high-resolution protein crystallography to examine the correlation between protein structure and biological activity of type IV pilins that are assembled into pili used by bacteria for multiple purposes, including cellular adhesion during infection. It was during these studies that Dr. Audette identified the generation of protein nanotubes from the engineered pilin monomers. Dr. Audette also studied the process of bacterial conjugation or lateral gene transfer, using the F-plasmid conjugative system of Escherichia coli. Current research directions include structure/function studies of proteins involved in bacterial conjugation systems, the structural and functional characterization of several type IV pilins (the monomeric subunit of the pilus), their assembly systems, and adapting these unique protein systems for applications in bionanotechnology. Dr. Audette has previously served as co-editor-in-chief of the Journal of Bionanoscience (2007–2010).

Israel Rubinstein, MD, is professor of medicine at the College of Medicine, University of Illinois at Chicago (USA). He is member of the section of pulmonary, critical care, allergy and sleep medicine, department of medicine, University of Illinois at Chicago, and attending physician at the University of Illinois Hospital & Health Sciences System and Jesse Brown VA Medical Center in Chicago. Dr. Rubinstein is the associate chief of staff for research and development at the Jesse Brown VA Medical Center. Prior to his appointment at the University of Illinois at Chicago, he was associate professor of medicine at the University of Nebraska Medical Center in Omaha, Nebraska, USA. Dr. Rubinstein received his medical degree from the Hebrew University-Hadassah School of Medicine in Jerusalem, Israel. He was a medical resident in Israel, fellow in respirology at the University of Toronto and a research fellow at the Cardiovascular Research Institute, University of California at San Francisco. Dr. Rubinstein holds 18 issued and pending patents and has authored close to 200 peer-reviewed papers in scientific journals. Dr. Rubinstein’s funded research endeavors center around nanomedicine and targeted drug delivery with specific focus on lipid-based products and repurposing. Currently, he serves as editor-in-chief of Nanotechnology, Science and Applications; associate editor of the International Journal of Nanomedicine and editorial board member of several scientific journals. Dr. Rubinstein is member of the scientific advisory board of the International Academy of Cardiology. He is a fellow of the American Heart Association as well as the American College of Physicians and the American College of Chest Physicians. In addition, he is member of the American Thoracic Society, American Physiological Society, American Society for Pharmacology and Experimental Therapeutics, and American Microbiology Society. Dr. Rubinstein is a board member and director of Advanced Life Sciences, a publicly traded biopharmaceutical company based in Woodridge, Illinois (USA). He is a co-founder of ResQ Pharma, an emerging clinical stage pharmaceutical company focusing on repurposing FDA-approved drugs for cardiopulmonary resuscitation and drug overdoses.

Name: Handbook of Clinical Nanomedicine: From Bench to Bedside (Hardback)Pan Stanford 
Description: Edited by Raj Bawa, Gerald F. Audette, Israel Rubinstein. The enormous advances in nanomedicine in the past decade have necessitated a growing need for an authoritative and comprehensive reference that can be relied upon by scientists, clinicians, students, and policy makers alike. Handbook of Clinical...
Categories: Biomedical Engineering, Nanoscience & Nanotechnology, Biomaterials